

Background: Renal involvement is a clinically significant manifestation in rheumatoid arthritis (RA) patients with potential influence on the treatment, prognosis and outcome of this disease while rare publications are available on kidney damage in RA [1,2].

Objectives: To estimate the frequency and characteristics of renal involvement and causes of death in RA patients on the basis of autopsy data reports and postmortem microscopic examinations.

Methods: We have analyzed 21,814 autopsy data reports performed during 10-year period (2001-2010) and 6,720 cases of autopsy performed 5 years later (2016-2018) in the Minsk City Clinical Pathologicalanatomic Bureau (The Republic of Belarus).

Results: For the period 2001-2010 autopsies were performed in 110 RA patients: 91 women and 19 men of 67.0 (13.1) years old, M (SD). Renal involvement was revealed in 75 patients (68.2%). The most common type of renal involvement was secondary AA amyloidosis - 44 patients (40%). Other types of revealed renal lesions (n=31, 28.2%) were mesangial proliferative glomerulonephritis (n=3; 2.7%), nephroangiosclerosis (n=14, 12.8%), tubulointerstitial nephritis (n=2, 1.8%), chronic pyelonephritis (n=10, 9.1%) and renal vessel vasculitis (n=2, 1.8%). The main cause of death in RA patients with amyloidosis was end-stage renal disease (ESRD, 43.2%), whereas in other patients the common causes of death were cardiovascular events (43.2%) and secondary infections (33.3%). In case of secondary amyloidosis the deposits of amyloid were found in kidney of all RA patients (100%), in adrenal glands – in 36.4% and in spleen – in 34.1% of RA patients. Amyloid deposits in other internal organs were not nearly as common.

In 2016-2018 50 patients with RA have been autopsied with mean age of death 72.0 (15.2) years old. Renal involvement was revealed in 34 (68.0%) of autopsies: as secondary amyloidosis in 29 patients (58.0%) and as focal segmental glomerulosclerosis or mesangial proliferative glomerulonephritis in 5 patients (10.0%). The most common cause of death in this group of RA patients were cardiovascular events (58.0%), fatal infectious complications developed in 16.0% of patients, ESRD was revealed only in 4.0% of patients.

Conclusion: 1. We have revealed an increase in secondary amyloidosis frequency in RA patients over the studied period of time from 40% to 58% (p=0.041, Fisher’s exact test) while ESRD as a cause of death in RA patients decreased from 17.3% to 4% (p=0.023, Fisher’s exact test). 2. Secondary amyloidosis is the most common type of renal involvement in RA according to the autopsy data.

REFERENCES

Disclosure of Interests: None declared

AB0279

DIFFERENCE BETWEEN PATIENT'S GLOBAL HEALTH AND PATIENT'S GLOBAL ASSESSMENT OF DISEASE ACTIVITY, AND DIFFERENT FACTORS INFLUENCE ON THESE SCALES IN RHEUMATOID ARTHRITIS PATIENTS
Naohiro Suzuki1,2, Yuki Mizutani1, Kentaro Noda1, Yasuo Suzuki1, Ayako Nakajima1,1, Mie University Hospital, Center for Rheumatic diseases, Tsu city, Mie, Japan; 2Tokyo Women’s Medical University, Department of Rheumatology, Tokyo, Japan

Background: Evaluation of rheumatoid arthritis (RA) activity is crucial measurement in achieving remission or low disease activity. Visual analogue scale (VAS) by patient’s evaluation has been used for the outcome measure for RA patients because of its feasibility, reliability, sensitivity to change, and it directly reflects the patient’s overall perspective. Patient’s evaluation is a component of multiple composite indices used in assessing RA activity and treatment response. There are two measurements that patient’s evaluation. One is patient’s global assessment of disease activity (PtGA), and the other is patient’s assessment of global health (PtGH)1. PtGA was originally developed as a component of American College of Rheumatology Core Set and used for Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI); while PtGH was originally developed as a component of 28-joint Disease Activity Score (DAS28). PtGA and PtGH have been considered equivalent in a
large scale of study\(^2\). In daily practice or observation, ‘patient’s VAS’ is usually used without specifying whether it refers to PtGA or PtGH. The factors which influence the change in PtGA or PtGH have not been demonstrated concomitantly in daily practice.

**Objectives:** We investigated the difference between PtGA and PtGH, especially each change obtained after intensification of treatment in 12 weeks and identified the factors that influence on each measurement in RA patients.

**Methods:** Consecutive patients were enrolled to this retrospective study at our hospital from October 2017 to September 2018. Demographic and clinical data at enrollment as well as treatment regimens were collected by review of medical charts. At first, we examined the baseline data and the changes in 12 weeks of PtGA and PtGH in their relations. The second, we divided those patients into two subsets according to medications intensified by metotrexate (MTX) subset and biological disease-modifying anti-rheumatic drugs (DMARDs) or janus kinase (JAK) inhibitor (BJ) subset. We compared the difference of the changes in PtGA from the baseline to 12 weeks ($\Delta$PtGA) and those in PtGH ($\Delta$PtGH) between MTX subset and BJ subset. Finally, the logistic regression analysis was performed to identify factors that differently influence for each scale in 12 weeks.

**Results:** Consecutive 38 RA patients were enrolled. Women were 76%. The median age (IQ) was 66.5 [55-76] years old. Disease duration was 2.5 [1-15] years. DAS28 was 2.61 [2.02-3.17]. SDAI was 16.8 [11.1-24.6] and CDAI was 15.3 [9.3-23.9], MTX was initiated or increased in 24 patients (63%). The baseline median dose of MTX was 6 [3.5-8] mg/week. Biologics or JAK inhibitor were initiated in 8 patients (21%); tocilizumab (n=5), golimumab (n=1), abatacept (n=1) and tofacitinib (n=1). Other DMARDs were used in 6 patients (16%). $\Delta$PtGH in 12 weeks was -1.68 (p<0.01), and $\Delta$PtGA in 12 weeks was -2.22 (p<0.01). $\Delta$PtGH and $\Delta$PtGA correlated significantly ($r=0.785$, $p<0.01$). $\Delta$PtGA in MTX subsets was not different from that in BJ subsets in (p=0.50) and $\Delta$PtGH was not either (p=0.57). No significant improving factor in $\Delta$PtGA was identified, whereas, woman (p=0.05) and usage of steroid (p=0.01) were improving factors in $\Delta$PtGH.

**Conclusion:** Intensification of treatment significantly improved both $\Delta$PtGA and $\Delta$PtGH but we need to pay attention as there were different improving factors between these two patient’s measurement.

**REFERENCES**


**Disclosure of Interests:** Naohiro Sugitani: None declared, Kentaro Noda: None declared, Yasuo Suzuki: None declared, Yuki Mizutani: None declared, Diane Lacaille1. Arthritis Research Canada, Richmond, Canada; 2University of British Columbia, Vancouver, Canada

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory disorder which if not managed properly leads to joint destruction, disability, poor quality of life and premature mortality. Disease modifying antirheumatic drugs (DMARDs) have considerably improved disease outcome in RA. However, poor patient compliance significantly limits the benefits that could be accrued from DMARDs. In a technology driven era, with more people having access to smart phones, unique opportunities exist for use of phone-based technologies to improve patient care in chronic diseases. This study aims to investigate whether the use of HealthCius smartphone application for self management can influence quality of life for people with RA and improve inflammatory disease activity.

**Objectives:** To investigate the impact of smartphone application (HealthCius) on inflammatory disease activity and quality of life in RA.

**Methods:** 38 RA patients fulfilled the American College of Rheumatoid Arthritis Classification Criteria were recruited. Subjects were randomized into 2 groups. First, having access to a smart phone were assigned to the intervention group using the Healthcius application (n=23) and second, the control group not using the application (n=15). The patients in two groups received standard treatment of RA. The application was designed after obtaining feedback from health care providers, patient counselors and RA patients using a questionnaire. To the patients, the app was their individual treatment plan. It helped them comply with the plan by providing an easy to refer checklist, reminders, alerts and a visual dashboard of their progress through the day. The app served as the doctor’s virtual assistant inside the patient’s smart phone. For the doctor, it was a live dashboard of all patients and their real time compliance levels. The data reported by the patients was available to the doctor in the form of time sliced charts and trend lines. Therefore, this app is designed to leverage technology to shift the patients’ focus every day on to their treatment plan thereby driving up compliance and better health outcomes.

**Outcome measures** included erythrocyte sedimentation rate (ESR), C-Reactive protein (CRP), disease activity score (DAS28) and health assessment questionnaire (HAQ-DI) at baseline and at 12 weeks.

**Disclosure of Interests:** None declared. Diane Lacaille1. Arthritis Research Canada, Richmond, Canada; 2University of British Columbia, Vancouver, Canada

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2019-eular.5945

**AB0282**

**SYSTEMATIC REVIEW OF STUDIES REPORTING ON COGNITIVE FUNCTION IN RHEUMATOID ARTHRITIS COMPARED TO THE GENERAL POPULATION**

**Teresa Szlachcica,1,2 Li Linda,1 Teresa Liu-Ambrose,1 Hui Xie,1 Kiana Yazdani1, Diane Lacaille1,1 Arthritis Research Canada, Richmond, Canada; 2University of British Columbia, Vancouver, Canada

**Background:** Rheumatoid arthritis (RA) patients often complain of ‘brain fog’ as a symptom when their disease activity is greater. The exact areas of cognition that this ‘brain fog’ means are not yet understood. Previous studies have found that people with RA have lower cognitive function (CF) than healthy controls and age based population norms. A study by Shin et al which looked at prevalence of cognitive impairment...